Back to search

Almond Mushroom, ABM · 2023 · Randomized Controlled Trial

Medium relevance

A randomized controlled trial of supervised remotely-delivered attention bias modification for posttraumatic stress disorder.

Agaricus blazei

Liver support
SpeciesAlmond Mushroom, ABM
JournalPsychological medicine
Year2023

Key points

  • BACKGROUND: Many individuals with posttraumatic stress disorder (PTSD) have limited access to first-line treatments, warranting the development of remotely-delivered treatments
  • Attention bias modification (ABM), targeting perturbed threat-related attentional patterns, shows promise when delivered in-person
  • However, previous studies found ABM to be ineffective when delivered remotely
  • We expected to replicate the results of in-clinic trials, in which ACT outperformed ABM for PTSD. METHODS: In this double-blinded, parallel-group randomized controlled trial, 60 patients diagnosed with PTSD were randomized (ABM n = 30; ACT n = 30)
  • Symptoms were assessed pre- and post-treatment with Clinician-Administered PTSD Scale 5 (CAPS-5) severity score and PTSD diagnosis as the primary outcomes
  • RESULTS: Significant decrease in CAPS-5 severity scores and PTSD diagnosis was observed following both ACT and ABM with no between-group difference

Metadata-grounded summary

Citation abstract

BACKGROUND: Many individuals with posttraumatic stress disorder (PTSD) have limited access to first-line treatments, warranting the development of remotely-delivered treatments. Attention bias modification (ABM), targeting perturbed threat-related attentional patterns, shows promise when delivered in-person. However, previous studies found ABM to be ineffective when delivered remotely. Randomized clinical trials usually applied two variations of ABM: ABM away from threat or attention control training (ACT) balancing attention between threat-related and neutral stimuli. We tested remotely-delivered ACT/ABM with tighter supervision and video-based interactions that resemble in-clinic protocols. We expected to replicate the results of in-clinic trials, in which ACT outperformed ABM for PTSD.

METHODS: In this double-blinded, parallel-group randomized controlled trial, 60 patients diagnosed with PTSD were randomized (ABM n = 30; ACT n = 30). Patients performed eight bi-weekly remotely-delivered supervised ABM/ACT sessions. Symptoms were assessed pre- and post-treatment with Clinician-Administered PTSD Scale 5 (CAPS-5) severity score and PTSD diagnosis as the primary outcomes. Current depressive episode, current anxiety-related comorbidity, and time elapsed since the trauma were examined as potential moderators of treatment outcome.

RESULTS: Significant decrease in CAPS-5 severity scores and PTSD diagnosis was observed following both ACT and ABM with no between-group difference. Patients without depression or whose trauma occurred more recently had greater symptom reduction in the ACT than the ABM group.

CONCLUSIONS: Contrary to our expectation, symptoms decreased similarly following ACT and ABM. Moderator analyses suggest advantage for ACT in non-depressed patients and patients whose trauma occurred more recently. Further refinements in remotely-delivered ABM/ACT may be needed.

Citation

Alon Y, Azriel O, Pine DS, Bar-Haim Y (2023). A randomized controlled trial of supervised remotely-delivered attention bias modification for posttraumatic stress disorder. Psychological medicine https://doi.org/10.1017/S003329172200023X PMID: 35132952

Open citation